Abstract:Hemophilia A is a hereditary disorder caused by various mutations in factor VIII gene resulting in either a severe deficit or total lack of the corresponding activity. Recent success in gene therapy of a related disease, hemophilia B, gives new hope that similar success can be achieved for hemophilia A as well. To develop a gene therapy strategy for the latter, a variety of model systems are needed to evaluate molecular engineering of the factor VIII gene, vector delivery efficacy and safety-related issues. Typically, a tissue culture cell line is the most convenient way to get a preliminary glimpse of the potential of a vector delivery strategy. It is then followed by extensive testing in hemophilia A mouse and dog models. Newly developed hemophilia A sheep may provide yet another tool for evaluation of factor VIII gene delivery vectors. Hemophilia models based on other species may also be developed since hemophiliac animals have been identified or generated in rat, pig, cattle and horse. Although a genetic nonhuman primate hemophilia A model has yet to be developed, the non-genetic hemophilia A model can also be used for special purposes when specific questions need to be addressed that cannot not be answered in other model systems. Hemophilia A is caused by a functional deficiency in the factor VIII gene. This X-linked, recessive bleeding disorder affects approximately 1 in 5000 males [1-3]. Clinically, it is characterized by frequent and spontaneous joint hemorrhages, easy bruising and prolonged bleeding time. The coagulation activity of FVIII dictates severity of the clinical symptoms. Approximately 50% of all cases are classified as severe with less than 1% of normal levels of factor VIII detected [4]. This deficiency may lead to spontaneous joint hemorrhages or life-threatening bleeding. In contrast, patients with 5-30% of normal factor VIII activity exhibit mild clinical manifestations.

A Quick and Efficient Method to Generate Hemophilia B Mouse Models by the CRISPR/Cas System

CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A

Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro

Long-term Correction of Hemophilia B Through CRISPR/Cas9 Induced Homology-Independent Targeted Integration

Low-dose AAV-CRISPR-mediated Liver-Specific Knock-in Restored Hemostasis in Neonatal Hemophilia B Mice with Subtle Antibody Response

[Generation of Factor VIII Gene Knockout Mouse by Tetraploid Embryo Complementation Technology].

Long-term correction of haemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy

Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation

Porcine model of hemophilia A

AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B

High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics

Efficient Transfer and Expression of Human Clotting Factor IX Cdna in Neonatal Hemophilia B Mice Mediated by VSV-G Pseudotyped Retrovirus

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

In Vitro and in Vivo Model Systems for Hemophilia A Gene Therapy.

Precise and Rapid Validation of Candidate Gene by Allele Specific Knockout With CRISPR/Cas9 in Wild Mice